PTC Therapeutics (NASDAQ:PTCT) Downgraded by Bank of America Co. – 3 stars to Underperform

0
137

PTC Therapeutics stock has undergone multiple analysts rating changes in the recent past.  PTC Therapeutics Downgraded by Bank of America Co. – 3 stars on 10/18/2021. In a note to investors, the firm issued a new rating of Underperform. The analysts previously had rating of Neutral.

Shares of PTC Therapeutics traded up $0.90 on Friday, reaching $38.09. 4388 shares of the stock traded hands, compared to its average volume of 449298. Shares of PTC Therapeutics were trading at $38.09 on Friday. The firm’s 50 day moving average is $39.91 and its 200 day moving average is $47.09.PTC Therapeutics has a 12 month low of $37.19 and a 12 month high of $70.82. While on yearly highs and lows, PTC Therapeutics’s today has traded high as $38.25 and has touched $37.19 on the downward trend. See More Analyst Rating at: RATING

PTC Therapeutics Earnings and What to expect: 

PTC Therapeutics last released its earnings results on July 29th, 2021. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.84) by $0.16. The company had revenue of $116.68 million for the quarter, compared to the consensus estimate of $105.65 million. PTC Therapeutics has generated ($6.50) earnings per share over the last year (($5.62) diluted earnings per share). Earnings for PTC Therapeutics are expected to grow in the coming year, from ($7.07) to ($3.61) per share. PTC Therapeutics has confirmed that its next quarterly earnings report will be published on Thursday, October 28th, 2021. PTC Therapeutics will be holding an earnings conference call on Thursday, October 28th at 4:30 PM Eastern. Interested parties can .

Earnings for PTC Therapeutics are expected to grow in the coming year, from ($7.07) to ($3.61) per share. The P/E ratio of PTC Therapeutics is -6.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of PTC Therapeutics is -6.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. PTC Therapeutics has a P/B Ratio of 5.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

PTC Therapeutics (NASDAQ:PTCT) Moving Average Technical Analysis

5 day Moving Average is $37.27 And 5 day price change is $1.36 (3.70%)  with average volume for 5 day average is 327,880. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $38.32 and 20 day price change is -$4.54 (-10.65%) and average 20 day moving volume is 480,975. 50 day moving average is $39.91  and 50 day price change is -$1.80 ( -4.51%)  and with average volume for 50 days is : 436,042. 200 day moving average is $47.09  and 200 day price change is -$22.99 (-37.64%)  and with average volume for 200 days is : 498,181.

Other owners latest trading in PTC Therapeutics :

  • On 10/7/2021 shares held by Berman Capital Advisors LLC were 795 which equates to market value of $29K and appx 0.00% owners of PTC Therapeutics
  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 71,948 which equates to market value of $3.04M and appx 0.00% owners of PTC Therapeutics
  • On 8/30/2021 shares held by Integral Health Asset Management LLC were 110,100 which equates to market value of $4.65M and appx 1.30% owners of PTC Therapeutics
  • In total Institutional ownership equates to There is no enough data Institutional Ownership Percentage for PTC Therapeutics

See More Analyst Rating at: RATING